To date, tissue plasminogen activator (tPA) is the only clinically effective drug approved by the Food and Drug Administration (FDA) for ischemic stroke (Zhao et al., 2017; Xu et al., 2018). This evidence concerns the gene PLAT and ischemic stroke.